Research reveals most medtech companies (83%) rely on manual approaches to share information with study stakeholders, such as email, portals, and paper.
Veeva Systems has released its first MedTech Clinical Benchmark Report, which reveals that most medtech companies (83%) are still relying on inefficient and time-consuming manual approaches to share information with study stakeholders.
Research reveals most medtech companies (83%) rely on manual approaches to share information with study stakeholders, such as email, portals, and paper. Manual methods of sharing information slow down study execution and data analysis, increasing the time and costs necessary to complete trial activities. With regulations like EU MDR and IVDR requiring more clinical evidence and performance data, there is a near-term opportunity to advance medtech studies to be faster and more efficient.
The report highlights key areas for improvement and progress made in medtech clinical research, including:
“The medtech industry has a significant opportunity to modernise clinical systems and processes for faster access to trial data,” said Kevin Liang, vice president, Vault Clinical strategy, Veeva MedTech. “As more organisations prioritise digital clinical technologies, medtech can improve collaboration with stakeholders and drive trial efficiency, productivity, and compliance.”
The Veeva MedTech Clinical Benchmark study examined how organisations—ranging from emerging to large device and diagnostics companies—manage clinical processes, study site collaboration, and trial data to ensure compliance and speed. This report includes insights from more than 135 clinical medtech professionals worldwide, outlining current challenges and near-term priorities associated with clinical trial conduct. See the full report, which investigates how medtech companies are managing clinical operations, outsourcing, post-market clinical follow-up, and modernisation.